In the report by Guardiola and colleagues,1 a switch in protease inhibitor (PI) therapy for reasons other than therapeutic failure occurred in 74% of patients who were treated with PI-based regimens. The therapeutic strategy in these patients needs careful assessment before PI changes, since the patients may be put at greater risk for therapeutic failure after therapy change.
Butcher D, Greene J, Duong P, Markson L. Virologic Response Associated With a Change in Protease Inhibitor Therapy. Arch Intern Med. 2000;160(3):393-394. doi: